Rolipram

Research use only, not for human use.

A potent, selective inhibitor of phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

A potent, selective inhibitor of phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively; increases phosphorylation of CREB in U937 cells in a dose-dependent fashion, dose-dependently inhibits the IFN-gamma-stimulated phosphorylation of p38 MAPK with IC50 of 290 nM; inhibits TNF production, attenuates carrageenan-induced paw inflammation in mice.Asthma Phase 2 Clinical

SB95952;ZK62711;(R,S)-Rolipram;SB 95952;ZK 62711;SB-95952;ZK-62711

Angiogenesis

PDE

PDE4B;PDE4D

Inflammation/Immunology

Asthma

61413-54-5

275.34

C16H21NO3

>98% (HPLC)

DMSO: ≥ 41 mg/mL

O=C1NCC(C2=CC=C(OC)C(OC3CCCC3)=C2)C1

2-Pyrrolidinone, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-

(-20℃)

With Ice Pack

≥ 2 years